The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 Presidents Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 Presidents Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Trial Academy Master Class 6.0
    • The Business Of Law
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

Nearly One-Third of Chemotherapy Used is Prescribed Off-Label

Posted on February 25, 2013 by Andrew Findley

NewsInferno; February 20, 2013

Some one-third of the chemotherapy drugs used to treat cancer were never approved by federal regulators to fight the cancers they are used for, according to an emerging study.

Chemotherapy drugs, approved by the U.S. Food and Drug Administration (FDA) to fight specific cancers, are often prescribed off-label to treat other tumors for which the drugs are not approved, explained Reuters Health, As we’ve explained, physicians are free to prescribe drugs in a so-called “off-label” way, meaning that an approved medication may be prescribed for a non-approved purpose.

Chemotherapies are types of drugs used to destroy or slow down the growth of cancer cells, which rapidly increase and divide, explained WebMD. The drugs are also known to damage healthy and rapidly dividing cells such as those lining the mouth or intestines or that cause hair to grow. Chemotherapies are known to cause significant side effects.

Chemotherapy can, depending on the cancer type and its stage, cure or control cancer or ease it symptoms and can be used alone or in collaboration with surgery, radiation therapy, or biological therapy, WebMD noted. The type of chemotherapy used depends on the type of cancer involved; some drugs are used in the treatment of a broad array of cancers. While others are used for one or two specific cancers.

Researchers questioned of physicians have been prescribing chemotherapies—very costly and toxic drugs—for unapproved uses, said the study team, which was led by Rena Conti, an assistant professor of health policy and economics at the University of Chicago, said Reuters Health. “The main criticism of off-label prescribing has been the concern that it jeopardizes patient safety because the full risk-benefit ratio is often not completely understood,” wrote University of Toronto’s Dr. Monika Krzyzanowska, according to Reuters Health. Krzyzanowska published an editorial accompanying the study that appeared in the Journal of Clinical Oncology yesterday.

Despite this, said Conti, billions of dollars are spent on off-label chemotherapies and are wasted. “We don’t know what the outcomes are. We can’t make a judgment of whether the off-label use we document … is appropriate or inappropriate,” Conti said, wrote Reuters Health.

For the study, the team used a national prescription database from United States oncologists to estimate how the most commonly used intravenous or injected chemotherapies were used in 2010. The researchers discovered that 10 chemotherapies were patent-protected from competition and ranged from nearly 500,000 doses of Genentech’s Avastin (bevacizumab), which is approved to treat brain, colorectal, lung, and kidney cancers, to about 53,000 doses of Celegene’s Vidaza (azacitidine), which is used in the treatment of specific blood disorders, said Reuters Health. The study found that 70 percent of the doses were used for approved treatments; 30 percent were used off-label.

The researchers also reviewed off-label chemotherapies use and how those uses were supported by the National Comprehensive Care Network (NCCN), which publishes its own cancer care guidelines, said Reuters Health. The team learned that 14 percent of chemotherapies were prescribed off label and supported by the NCCN’s expert opinion; 10 percent were prescribed with no NCCN or FDA support. This is significant because, as Conti explained to Reuters Health, physicians will follow guidelines from expert organizations when insufficient data is available for the federal regulator to make a decision; for instance, when treating rare diseases that are challenging to research in a clinical trial, said Reuters Health.

Conti and her colleagues noted that some researchers have criticized NCCN recommendations, given both potential delays in releasing guidelines based on current data and possible conflicts of interests, Reuters Health explained. Of the $12 billion spent on chemotherapies in 2010, $4.5 billion was spent on off-label chemotherapies and $2.5 billion was spent on non-NCCN-supported uses.

“To me it’s a little troubling that so many drugs are given in areas where there is not a lot of data to back it up,” Dr. Nancy Keating, a cancer researcher not involved with the research, told Reuters Health. “The tricky thing is patients with cancer and their doctors are looking for anything with a benefit. So I think they’re sometimes willing to try things where there isn’t as much data as you would like,” said Keating, who is from Boston’s Harvard Medical School and Brigham and Women’s Hospital.

Conti said the research did not conclude if patients prescribed on-label chemotherapy fared better than those receiving off-label chemotherapy. “What our study basically does is highlight this proportion of use that is off-label and endorsed by expert opinion, or off-label and not endorsed by expert opinion,” Conti told Reuters Health. Conti pointed out that the study also revealed that the use of chemotherapies is driven by FDA approval and expert opinion, while treatments prescribed with no expert or FDA backing, may be over a lack of available treatments, said Reuters Health.

http://www.newsinferno.com/?p=42890

Posted in Blog, Newsletter

Comments are closed.

Recent Posts

The New Mexico Supreme Court Upholds $165 Million Damage Awards in a Deadly FedEx Crash

The New Mexico Supreme Court Upholds $165 Million Damage Awards in a Deadly FedEx Crash

May 20th, 2022

The New Mexico Supreme Court on Thursday upheld $165 million of jury awards against FedEx in a wrongful-death lawsuit stemmin[Read More...]
Noom Reaches a $56 Million Class Action Settlement Over Its Autorenewal and Cancellation Policy

Noom Reaches a $56 Million Class Action Settlement Over Its Autorenewal and Cancellation Policy

May 20th, 2022

Weight-loss program Noom has agreed to a $56 million settlement to resolve class action claims regarding its autorenewal and [Read More...]
Virginians Will Receive $489 Million in a Payday Loan Settlement

Virginians Will Receive $489 Million in a Payday Loan Settlement

May 18th, 2022

Online payday loan companies that charged as much as 919% interest will spend $489 million to reimburse some 555,000 borrower[Read More...]
The State of Minnesota Will Pay $1.5 Million to a Man Who Alleged Excessive Force During an Arrest

The State of Minnesota Will Pay $1.5 Million to a Man Who Alleged Excessive Force During an Arrest

May 18th, 2022

Minneapolis has agreed to pay $1.5 million to a man who said police used excessive force when he was arrested during the prot[Read More...]
A $230 Million Settlement Is Reached Over a 2015 Southern California Oil Spill

A $230 Million Settlement Is Reached Over a 2015 Southern California Oil Spill

May 16th, 2022

The owner of an oil pipeline that spewed thousands of barrels of crude oil onto Southern California beaches in 2015 has agree[Read More...]

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.